|
First-line bevacizumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimisation analysis |
Nerich V, Bazan F, Compagnat F, Dobi E, Villanueva C, Chaigneau L, Perrin S, Voidey A, Pivot X, Limat S |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Nerich V, Bazan F, Compagnat F, Dobi E, Villanueva C, Chaigneau L, Perrin S, Voidey A, Pivot X, Limat S. First-line bevacizumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimisation analysis. Anticancer Research 2012; 32(8): 3547-3552 Original Paper URL S. Limat, Department of Pharmacy, University Hospital, 3 Boulevard Fleming, 25030 BESANCON Cedex, France. E-mail: Indexing Status Subject indexing assigned by NLM MeSH Aged; Antibodies, Monoclonal, Humanized /administration & Antineoplastic Combined Chemotherapy Protocols /economics /therapeutic use; Bevacizumab; Breast Neoplasms /drug therapy /pathology; Bridged Compounds /administration & Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Metastasis; Taxoids /administration & dosage /economics; dosage /economics; dosage /economics AccessionNumber 22012033823 Date bibliographic record published 04/01/2013 |
|
|
|